180 related articles for article (PubMed ID: 7790953)
1. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
[TBL] [Abstract][Full Text] [Related]
2. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Ruottinen H; Ruotsalainen U; Rinne UK
Synapse; 1995 Oct; 21(2):97-103. PubMed ID: 8584980
[TBL] [Abstract][Full Text] [Related]
3. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
[TBL] [Abstract][Full Text] [Related]
4. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
5. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain.
Bergström KA; Halldin C; Hall H; Lundkvist C; Ginovart N; Swahn CG; Farde L
Eur J Nucl Med; 1997 Jun; 24(6):596-601. PubMed ID: 9169564
[TBL] [Abstract][Full Text] [Related]
8. Cocaine congeners as PET imaging probes for dopamine terminals.
Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
[TBL] [Abstract][Full Text] [Related]
9. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
10. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
11. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
Haapaniemi TH; Ahonen A; Torniainen P; Sotaniemi KA; Myllylä VV
Mov Disord; 2001 Jan; 16(1):124-30. PubMed ID: 11215571
[TBL] [Abstract][Full Text] [Related]
12. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
13. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
Rinne JO; Bergman J; Ruottinen H; Haaparanta M; Eronen E; Oikonen V; Sonninen P; Solin O
Synapse; 1999 Feb; 31(2):119-24. PubMed ID: 10024008
[TBL] [Abstract][Full Text] [Related]
14. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
[TBL] [Abstract][Full Text] [Related]
15. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756.
Laihinen AO; Rinne JO; Ruottinen HM; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Rinne UK
J Nucl Med; 1994 Dec; 35(12):1916-20. PubMed ID: 7989969
[TBL] [Abstract][Full Text] [Related]
16. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
17. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.
Winogrodzka A; Bergmans P; Booij J; van Royen EA; Stoof JC; Wolters EC
J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):294-8. PubMed ID: 12588911
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
[TBL] [Abstract][Full Text] [Related]
20. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
